Adherence, Safety, and Feasibility of HIV Pre-Exposure Prophylaxis Among Adolescent Men Who Have Sex With Men and Transgender Women in Brazil (PrEP1519 Study)

Imagem de Miniatura
Arquivos
art_DOURADO_Adherence_Safety_and_Feasibility_of_HIV_PreExposure_Prophylaxis_2023.PDF (866.93 KB)
Citações na Scopus
2
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER SCIENCE INC
Autores
DOURADO, Ines
SOARES, Fabiane
MAGNO, Laio
AMORIM, Leila
EUSTORGIO FILHO, Marcos
LEITE, Beo
GRECO, Dirceu
WESTIN, Mateus
TUPINAMBAS, Unai
MASSA, Paula
Citação
JOURNAL OF ADOLESCENT HEALTH, v.73, n.6, suppl.S, p.S33-S42, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Purpose: To evaluate the adherence, safety, and feasibility of pre-exposure prophylaxis (PrEP) in real-world settings among adolescent men who have sex with men (AMSM) and transgender women (ATGW). Methods: PrEP1519 is a single-arm, multicentric demonstration cohort study of daily oral PrEP among AMSM and ATGW aged 15 to 19 years in Brazil. Study visits occurred at baseline, weeks 4, 12, and then quarterly until 96 weeks. Descriptive statistics and a mixed logistic model for longitudinal data evaluated the factors associated with high adherence. Results: One thousand sixteenAMSMand ATGWaccessed the PrEP1519 clinics. Of those, 998 (98.2%) underwent clinical triage. Forty one were diagnosed with human immunodeficiency viruses (HIV) at baseline (4.0%) and 79 (7.9%) were not eligible for PrEP. Of the 878, 795 (90.5%) enrolled in PrEP, 82 (10.3%) were lost to follow-up, and 713 were included. Therewas no significant decrease in creatinine clearance; only two participants had grade-III aspartate aminotransferase elevation. Incident HIV infection occurred in eight participants (incidence rate [IR] = 1.64 per 100 person-years [PY]): two in 15-17 years (IR = 2.24 per 100 PY) and six in 18-20 years (IR = 1.51 per 100 PY). PrEP adherencewas higher among those with more years of schooling, those reporting no difficulties in PrEP use due to side effects, and who had low HIV risk perception in the past three months. Discussion: PrEP for AMSM and ATGW was safe and feasible in real-world settings. However, a higher IR among young adolescents and a higher adherence among less vulnerable people indicate the need for greater care, considering the specificities of this age group. (c) 2023 Society for Adolescent Health and Medicine.
Palavras-chave
PrEP, Adolescent, Men who have sex with men, Transgender women, Adherence, Safety, Feasibility
URI
https://observatorio.fm.usp.br/handle/OPI/58077
Referências
  1. Anderson PL, 2018, ANTIMICROB AGENTS CH, V62, DOI 10.1128/AAC.01710-17
  2. [Anonymous], 2022, Brasilia: Secretaria de Ciencia, Tecnologia, Inovacao e Insumos Estrategicos em Saude, Secretaria de Vigilancia em Saude
  3. [Anonymous], 2017, Protocolo Clinico e Diretrizes Terapeuticas para Profilaxia Pre-Exposicao (PrEP) de Risco a Infeccao pelo HIV
  4. Chandra-Mouli V, 2015, J ADOLESCENT HEALTH, V56, pS1, DOI 10.1016/j.jadohealth.2014.09.015
  5. Chou R, 2019, JAMA-J AM MED ASSOC, V321, P2214, DOI 10.1001/jama.2019.2591
  6. Coelho LE, 2021, AIDS BEHAV, V25, P3223, DOI 10.1007/s10461-021-03180-5
  7. DANGER, 2022, UNAIDS global AIDS Update 2022
  8. Dourado I, 2023, Cad Saude Publica, V39
  9. Felisbino-Mendes Mariana Santos, 2018, Rev. bras. epidemiol., V21, pe180013, DOI 10.1590/1980-549720180013.supl.1
  10. Ferraz D, 2023, ARCH SEX BEHAV, V52, P689, DOI 10.1007/s10508-022-02364-x
  11. Fonner VA, 2016, AIDS, V30, P1973, DOI 10.1097/QAD.0000000000001145
  12. Gill K, 2017, J INT AIDS SOC, V20, P116
  13. Haberer JE, 2015, AIDS, V29, P1277, DOI 10.1097/QAD.0000000000000647
  14. Hosek SG, 2017, JAMA PEDIATR, V171, P1063, DOI 10.1001/jamapediatrics.2017.2007
  15. Hosek SG, 2017, JAIDS-J ACQ IMM DEF, V74, P21, DOI 10.1097/QAI.0000000000001179
  16. Krakower D, 2019, J INT AIDS SOC, V22, DOI 10.1002/jia2.25250
  17. Lall P, 2015, J INT AIDS SOC, V18, P41, DOI 10.7448/IAS.18.2.19393
  18. Landovitz RJ, 2021, NEW ENGL J MED, V385, P595, DOI 10.1056/NEJMoa2101016
  19. Magno L, 2023, ARCH SEX BEHAV, V52, P703, DOI 10.1007/s10508-022-02371-y
  20. Magno L, 2023, SEX EDUC-SEX SOC LEA, V23, P409, DOI 10.1080/14681811.2022.2047017
  21. Massa P, 2023, J MED INTERNET RES, V25, DOI 10.2196/41881
  22. Rutstein SE, 2020, LANCET HIV, V7, pE721, DOI 10.1016/S2352-3018(20)30203-4
  23. Saffier IP, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2795-9
  24. Schaefer R, 2021, LANCET HIV, V8, pE502, DOI 10.1016/S2352-3018(21)00127-2
  25. Shehnaz SI, 2013, EPIDEMIOL BIOSTAT PU, V10, DOI 10.2427/8724
  26. Oliveira RLSE, 2023, CAD SAUDE PUBLICA, V39, DOI [10.1590/0102-311XEN176821, 10.1590/0102-311xen176821]
  27. Szwarcwald CL, 2022, REV SOC BRAS MED TRO, V55, DOI 10.1590/0037-8682-0231-2021
  28. U. D. O. H. A. H. Services, 2017, Division of AIDS (DAIDS) table for grading the severity of adult and pediatric adverse events
  29. United Nations, 2016, Resolution adopted by the general Assembly on 3 June 2015
  30. Van der Elst EM, 2013, AIDS BEHAV, V17, P2162, DOI 10.1007/s10461-012-0317-8
  31. Veloso VG, 2023, LANCET HIV, V10, pE84, DOI 10.1016/S2352-3018(22)00331-9
  32. Yager J, 2020, JAIDS-J ACQ IMM DEF, V84, P323, DOI 10.1097/QAI.0000000000002354
  33. Zhang J, 2022, LANCET HIV, V9, pE254, DOI 10.1016/S2352-3018(22)00030-3
  34. Zucchi EM, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0249293

Coleções
Artigos e Materiais de Revistas Científicas - FM/Outros
Artigos e Materiais de Revistas Científicas - LIM/39
Artigos e Materiais de Revistas Científicas - ODS/03